Medgenics MOVES Forward with Hepatitis D Drug and 2 More Stocks Hitting 52-Week Highs

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Medgenics Inc. Commo (MDGN) rises quickly following the company’s announcement that its Infradure Biopump has been given an Orphan Drug Designation from the FDA in order to treat hepatitis D.  This designation allows the company to be given grant money, obtain specific tax credits, seven years of market exclusivity, and possibly an expedited regulatory process. The designations has made Seeking Alpha contributor Ray Dirks label Medgenics as a prime takeout target.  The shares closed at $8.65, up $1.75 or 25.36% on the day. They have traded in a 52-week range of $2.08 to $8.60.

Don’t Miss: Is the Fed’s OPERATION TWIST the End-All Answer?

Raytheon Company (NYSE:RTN): Los Angeles County has chosen Raytheon to replace legacy emergency dispatch consoles with newer ones which can be easily expanded for innovative technologies for public safety like Long Term Evolution, which is a high-speed, wireless broadband data network. This $12.5M contract gives Raytheon the responsibility of replacing these consoles which should allow sheriff and fire departments to be more responsive, raise efficiency, and lower maintenance costs. The shares closed at $54.89, up $0.25 or 0.46% on the day. They have traded in a 52-week range of $38.35 to $55.00.

Triangle Capital Cor (NASDAQ:TCAP) has closed a subordinated debt investment in Xchange Technology totaling $6M. The shares closed at $21.45, down $0.16 or 0.74% on the day. They have traded in a 52-week range of $13.62 to $21.70.

Don’t Miss: Are Ford Motor and Coca-Cola Friending Facebook for the Long-Term?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business